Completed PHASE2 INTERVENTIONAL 2-arm NCT00594581

Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males

A Single-Site, Double-Blind, Phase II Trial to Investigate the Safety, Toleration, Systemic Exposure and Anti-Scarring Potential of Different Applications of Intradermal Juvista (Avotermin) in Male Subjects Aged 18-45 Years

Sponsor: Renovo

Conditions Cicatrix

Interventions Juvista (avotermin) plus placebo, standard-care (within-subject controls)

Updated 5 times since 2017 Last updated: Jan 2, 2008 Started: Oct 31, 2003 Completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00594581, this PHASE2 trial focuses on Cicatrix and remains completed. Sponsored by Renovo, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Renovo

Data source: Renovo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Manchester, United Kingdom